Boundless Begin Period Cash Flow from 2010 to 2024
| BOLD Stock | USD 2.59 0.07 2.78% |
Begin Period Cash Flow | First Reported 2016-09-30 | Previous Quarter 25.1 M | Current Value 31.9 M | Quarterly Volatility 65.1 M |
Check Boundless Bio, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Boundless Bio,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 909.1 K, Selling General Administrative of 11.5 M or Other Operating Expenses of 55.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Boundless financial statements analysis is a perfect complement when working with Boundless Bio, Valuation or Volatility modules.
Boundless | Begin Period Cash Flow |
Latest Boundless Bio,'s Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Boundless Bio, Common over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Boundless Bio,'s Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Boundless Bio,'s overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Boundless Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 44,825,387 | |
| Geometric Mean | 34,214,169 | |
| Coefficient Of Variation | 62.32 | |
| Mean Deviation | 25,417,106 | |
| Median | 38,913,000 | |
| Standard Deviation | 27,936,420 | |
| Sample Variance | 780.4T | |
| Range | 61.1M | |
| R-Value | (0.89) | |
| Mean Square Error | 178T | |
| R-Squared | 0.79 | |
| Slope | (5,545,955) | |
| Total Sum of Squares | 10926.2T |
Boundless Begin Period Cash Flow History
About Boundless Bio, Financial Statements
Boundless Bio, stakeholders use historical fundamental indicators, such as Boundless Bio,'s Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Boundless Bio, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Boundless Bio,'s assets and liabilities are reflected in the revenues and expenses on Boundless Bio,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Boundless Bio, Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 11.5 M | 10.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio, Common is a strong investment it is important to analyze Boundless Bio,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio,'s future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out the analysis of Boundless Bio, Correlation against competitors. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.